Pembrolizumab can now be used to treat triple negative breast cancer - a form of the disease that accounts for a quarter of breast cancer deaths.
A new drug could benefit hundreds of women suffering from one of the most aggressive forms of breast cancer.
Typically, the risk of triple negative breast cancer returning and spreading to other parts of the body in the first few years after treatment is higher, according to the charity Breast Cancer Now. Breast Cancer Now, which promotes research and carries out support, hailed the new treatment, saying that women with this type of breast cancer previously faced the"frightening reality of limited treatment options".
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: